According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology.

Next, we’ll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we’ll discuss two recent FDA drug approvals for patients with hematologic disorders.

Coverage of stories discussed this week on ascopost.com:

Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer

What Is the Best Palliation for End-Stage Lung Cancer?

FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma

FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia